Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Caribou Biosciences Inc(CRBU)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for CRBU
09/24/2026: CRBU (1-star) is currently NOT-A-BUY. Pass it for now.
Caribou Biosciences is a clinical-stage biotechnology company developing CRISPR-edited allogeneic cell therapies for oncology. The company’s primary strength lies in its proprietary chRDNA genome-editing platform, which aims to provide high precision in therapeutic applications. Its main growth story is centered on the potential of candidates like CB-010 to offer effective off-the-shelf treatments for cancer patients. However, as a pre-revenue entity, it faces significant risks including clinical trial failures, high capital requirements, and intense competition from larger pharmaceutical incumbents. Caribou is most suitable for risk-tolerant, growth-oriented investors and requires close monitoring of clinical data readouts and capital efficiency.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | High growth potential exists if clinical trials succeed, but execution risk is significant for a pre-revenue company. |
| Momentum investor | Strong fit while signal remains positive | The stock can experience rapid price movements based on clinical data releases and regulatory milestones. |
| Value investor | Weak fit | Valuation is difficult to derive using traditional metrics as the company has no earnings or positive cash flow. |
| Dividend investor | Weak fit | The company does not pay a dividend and is unlikely to do so in the near future. |
| Low-risk investor | Weak fit | Extreme volatility and clinical development risks make this unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical trial outcomes can cause massive fluctuations in market valuation. |
| Valuation risk | High | Speculative pricing makes the stock susceptible to corrections during market downturns. |
| Competition risk (Biotech) | Medium / high | Well-funded incumbents are aggressively developing competing cell therapies. |
| Business quality | Medium | The company has a strong technical foundation but lacks commercial execution experience. |
| Dividend income | Low / none | There is no income generation for shareholders. |
| Execution risk | High | Success depends entirely on the outcome of complex, high-stakes clinical trials. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -33.24% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/24/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 138.30M USD | Price to earnings Ratio - | 1Y Target Price 11.86 |
Price to earnings Ratio - | 1Y Target Price 11.86 | ||
Volume (30-day avg) 1.2M shares | Beta 2.28 | 52 Weeks Range 1.25 - 3.54 | Updated Date 09/24/2026 |
52 Weeks Range 1.25 - 3.54 | Updated Date 09/24/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.04 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Development | Advancement of CAR-T candidates; revenue would eventually come from therapeutic sales or licensing/milestone payments. | This is a long-term 'bet' on successful drug development; revenue is currently non-existent. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 58.00M | Price to Sales(TTM) 13.78 |
Enterprise Value 58.00M | Price to Sales(TTM) 13.78 | ||
Enterprise Value to Revenue 5.89 | Enterprise Value to EBITDA -36.94 | Shares Outstanding 107.21M | Shares Floating 102.91M |
Shares Outstanding 107.21M | Shares Floating 102.91M | ||
Percent Insiders 8.24 | Percent Institutions 44.9 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Caribou Biosciences Inc
Exchange NASDAQ | Headquarters Berkeley, CA, United States | ||
IPO Launch date 2021-07-23 | Co-Founder, CEO, President & Director Dr. Rachel E. Haurwitz Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 97 | Website https://cariboubio.com |
Full time employees 97 | Website https://cariboubio.com | ||
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.